1. A pharmaceutical solution formulation, gel, or semisolid or suspension comprising a peptide that acts as a ligand of one or more melanocortin receptors, or a pharmaceutically acceptable salt thereof, wherein the peptide forms a depot after subcutaneous or intramuscular administration subektu.2. A pharmaceutical composition according to claim 1, wherein said peptide in said solution forms a depot at the injection site after administration, which dissolves slowly released into the body fluid and bloodstream, and wherein said solution is completely aqueous, organic solution completely, the aqueous solution having an organic component, an aqueous solution having an inorganic component, or an aqueous solution, having both organic and inorganic komponenty.3. A pharmaceutical composition according to claim 1 or 2, wherein said peptide is soboyAc-Arg-cyclo (Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) -NH Ac-D-Arg-cyclo (Cys -D-Ala-His-D-Phe-Arg-Trp-Cys) -NH Ac-Tyr-Arg-cyclo (Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) -NH Ac -Tyr-D-Arg-cyclo (Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) -NH iligidantoin (Arg-Gly) -cyclo (Cys-Glu-His-D-Phe-Arg-Trp-Cys) -NH or a pharmaceutically acceptable soli.4. A pharmaceutical composition according to claim 3, wherein said peptide is Ac-Arg-cyclo (Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) -NH.5. A pharmaceutical composition according to claim 1 or 2, wherein said peptide is in the form pamoate soli.6. A pharmaceutical composition according to claim 5, further comprising an organic komponent.7. A pharmaceutical composition according to claim 6, wherein said organic component is an organic polymer, alcohol, DMSO, DMF or DMA.8. A pharmaceutical composition according to claim 7, wherein1. Фармацевтическая композиция раствора, геля, или полутвердого вещества, или суспензии, включающая пептид, который действует как лиганд одного или более рецепторов меланокортина, или ее фармацевтически приемлемая соль, в которой пептид образует депо после подкожного или внутримышечного введения субъ
